Equities research analysts expect Natera, Inc. (NASDAQ:NTRA) to post ($0.46) earnings per share for the current quarter, Zacks reports. Two analysts have made estimates for Natera’s earnings, with estimates ranging from ($0.50) to ($0.44). Natera posted earnings per share of ($0.50) in the same quarter last year, which would indicate a positive year over year growth rate of 8%. The business is scheduled to issue its next quarterly earnings report on Wednesday, November 8th.

On average, analysts expect that Natera will report full year earnings of ($2.02) per share for the current year, with EPS estimates ranging from ($2.08) to ($1.96). For the next financial year, analysts forecast that the company will post earnings of ($1.24) per share, with EPS estimates ranging from ($1.30) to ($1.18). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Natera.

Natera (NASDAQ:NTRA) last released its earnings results on Tuesday, August 8th. The medical research company reported ($0.52) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.52). Natera had a negative net margin of 62.64% and a negative return on equity of 137.46%. The company had revenue of $53.60 million for the quarter, compared to the consensus estimate of $50.57 million. During the same quarter in the previous year, the company earned ($0.46) EPS. Natera’s quarterly revenue was up 3.1% compared to the same quarter last year.

NTRA has been the subject of several recent research reports. Zacks Investment Research lowered Natera from a “hold” rating to a “sell” rating in a research report on Wednesday, July 12th. ValuEngine lowered Natera from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th. BidaskClub lowered Natera from a “buy” rating to a “hold” rating in a research report on Tuesday, July 25th. Cowen and Company reissued a “buy” rating and set a $14.00 price objective on shares of Natera in a research report on Friday, September 1st. Finally, Morgan Stanley lowered their price objective on Natera from $18.00 to $13.00 and set an “overweight” rating for the company in a research report on Monday, August 7th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. Natera presently has a consensus rating of “Hold” and an average target price of $14.45.

In other Natera news, insider Jonathan Sheena sold 120,000 shares of the firm’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $12.54, for a total transaction of $1,504,800.00. Following the completion of the transaction, the insider now owns 533,208 shares of the company’s stock, valued at $6,686,428.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 12.57% of the company’s stock.

A number of institutional investors have recently made changes to their positions in NTRA. Teachers Advisors LLC lifted its position in Natera by 5.0% during the fourth quarter. Teachers Advisors LLC now owns 44,224 shares of the medical research company’s stock valued at $518,000 after buying an additional 2,116 shares during the period. Nationwide Fund Advisors lifted its position in Natera by 7.3% during the first quarter. Nationwide Fund Advisors now owns 62,273 shares of the medical research company’s stock valued at $552,000 after buying an additional 4,246 shares during the period. Prudential Financial Inc. lifted its position in Natera by 185.9% during the first quarter. Prudential Financial Inc. now owns 73,820 shares of the medical research company’s stock valued at $654,000 after buying an additional 48,000 shares during the period. American International Group Inc. lifted its position in Natera by 7.1% during the first quarter. American International Group Inc. now owns 16,065 shares of the medical research company’s stock valued at $142,000 after buying an additional 1,068 shares during the period. Finally, Alliancebernstein L.P. lifted its position in Natera by 5.6% during the first quarter. Alliancebernstein L.P. now owns 26,600 shares of the medical research company’s stock valued at $236,000 after buying an additional 1,400 shares during the period. 59.79% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This story was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/09/28/0-46-eps-expected-for-natera-inc-ntra-this-quarter.html.

Natera (NASDAQ NTRA) traded up 5.38% on Wednesday, hitting $12.93. 231,249 shares of the company were exchanged. The company’s market capitalization is $688.17 million. Natera has a 52 week low of $7.88 and a 52 week high of $13.49. The stock has a 50 day moving average of $13.02 and a 200 day moving average of $13.02.

About Natera

Get a free copy of the Zacks research report on Natera (NTRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Natera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera Inc. and related stocks with our FREE daily email newsletter.